The European Medicines Agency (EMA) has released a draft guideline revision on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias for a six-month public consultation. The EMA considers dementia a key public health priority and sees early stage intervention and prevention of symptomatic disease as particularly worthy goals. This …